The 2026 American Diabetes Association (ADA) Standards of Care in Diabetes introduce updated recommendations for the pharmacological management of type 2 diabetes mellitus (T2DM). The guidelines highlight a shift toward comprehensive risk reduction, with increased focus on protecting cardiovascular, renal, and hepatic health while improving quality of care through advanced clinical technologies.
They also promote a patient-centered treatment strategy, encouraging early combination therapy and targeted interventions to reduce cardiovascular and renal complications.
This summary reviews the key evidence-based pharmacological recommendations for T2DM, categorized by strength of recommendation and clinical priority.
To access the full guideline, click here.